What's Happening With Masimo Stock?
Masimo stock (MASI) has faced a challenging year, trailing the broader market with a -3% annual return. While shares surged 34% yesterday following news of an acquisition by Danaher, this spike only p...
Fiscal Year: January - December
Masimo Corporation (MASI), listed on the NASDAQ, has a market capitalization of $. As of Feb 21, 2026, the stock is trading at $175.10 per share, offering investors a clear view of its current market value. Masimo Corporation is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of N/A , investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Masimo Corporation also offers a dividend yield of N/A , making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Masimo Corporation (MASI) may be overvalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for Masimo Corporation is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Masimo Corporation, Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Masimo Corporation is 48.01, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Masimo Corporation (MASI) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Masimo Corporation (MASI) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be overvalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Masimo Corporation (MASI) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Masimo Corporation. To access the full SS Score, consider upgrading your subscription.
Masimo Corporation is a significant player in the industry sector, with a market capitalization of $ and a competitive P/E ratio of N/A . Investors should compare these metrics with industry peers to gauge whether Masimo Corporation is outperforming or underperforming within its sector.
Masimo stock (MASI) has faced a challenging year, trailing the broader market with a -3% annual return. While shares surged 34% yesterday following news of an acquisition by Danaher, this spike only p...
As of Feb. 18, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Danaher will acquire pulse oximeter maker Masimo for $9.9 billion, the company said on Tuesday, as the contract research firm looks to bulk up its diagnostics portfolio.
IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI) (“Masimo”), a leading global medical innovator, today announced that it has entered into a definitive agreement pursuant to which Dan...
WASHINGTON, Feb. 17, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a global science and technology innovator, announced today that it has entered into a definitive agreement to acquire Masimo ...
Danaher (DHR) is nearing a ~$10B acquisition of Masimo (MASI), representing a significant premium to MASI's prior $7B market cap. Elliott Investment Management has built a >10% stake in Norwegian Crui...
The medical-device maker is expected to operate as a stand-alone company within Danaher's Diagnostics segment.
Masimo stock jumped on a report of a potential acquisition. The company is perhaps best known for its yearslong patent dispute with Apple.
U.S. stock futures fluctuated on Tuesday following Friday's mixed close. Futures of major benchmark indices were mixed at the beginning of the holiday-shortened week as the markets were closed on Mond...
US healthcare manufacturer Danaher is closing in a nearly $10 billion deal to acquire medical technology company Masimo , the Financial Times reported on Monday, citing people familiar with the matter...
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) will release fourth quarter and full year 2025 financial results for the period ended January 3, 2026, after the market closes on Thursday, Febru...
BOSTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Clairity, a U.S.-based medical technology company advancing AI-powered breast cancer risk assessment, today announced that its founder, Connie Lehman, MD, PhD...
Masimo Corporation (MASI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI) today announced select preliminary financial results for the fourth quarter and full-year ended January 3, 2026. Preliminary Fourth Q...
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that its management will participate in the J.P. Morgan 2026 Healthcare Conference on Wednesday, January 14, 2026 at 2:15 p.m. Pa...
Despite securing a massive $634 million legal victory against Apple Inc. (NASDAQ: AAPL), Masimo Corp. (NASDAQ: MASI) is flashing warning signals in its underlying fundamentals.
The healthcare sector of the U.S. stock market as a whole is cheaply priced, which can make it attractive to investors concerned that the S&P 500 has gotten too expensive several years into a bull mar...
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK , Dec. 5, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is invest...
Masimo Corp (NASDAQ: MASI) on Wednesday hosted its 2025 Investor Day. At the event, Masimo's management team provided an update on the company's long-term strategy.
Masimo Corporation (MASI) Analyst/Investor Day Transcript
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today hosted its 2025 Investor Day at the Company's headquarters. At the event, Masimo's management team provided an update on the Company's long...
IRVINE, Calif. , Nov. 18, 2025 /PRNewswire/ -- A team from Knobbe Martens led medical device pioneer Masimo (NASDAQ: MASI) to a victory over Apple in a dispute involving Masimo's patented heart monito...
DRC congratulates Knobbe Martens on a decisive jury verdict awarding its client Masimo more than $634 million in an Apple Watch patent infringement case.
A federal jury in California ruled Friday that Apple must pay medical device maker Masimo $634 million for infringing a patent on blood oxygen monitoring technology.
A federal jury in California said on Friday that Apple owes medical-monitoring technology company Masimo $634 million for infringing a patent covering blood-oxygen reading technology.
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
| Year | FCF Estimate | % | # Analysts |
|---|---|---|---|
| 2025 | 195.60M | 10.88% | Est @10.9% |
| 2026 | 214.80M | 9.82% | Analyst x1 |
| 2027 | 228.03M | 6.16% | Est @6.2% |
| 2028 | 239.74M | 5.14% | Est @5.1% |
| 2029 | 250.31M | 4.41% | Est @4.4% |
| 2030 | 259.47M | 3.66% | Est @3.7% |
| 2031 | 268.11M | 3.33% | Est @3.3% |
| 2032 | 276.42M | 3.10% | Est @3.1% |
| 2033 | 284.54M | 2.94% | Est @2.9% |
| 2034 | 292.03M | 2.63% | Est @2.6% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
| Year | FCF | Discount Factor | PV of Future FCF |
|---|---|---|---|
| 2023A | 50.10M | 1.00 | 50.10M |
| 2024A | 176.40M | 1.00 | 176.40M |
| 2025E | 195.60M | 1.09 | 179.19M |
| 2026E | 214.80M | 1.19 | 180.26M |
| 2027E | 228.03M | 1.30 | 175.31M |
| 2028E | 239.74M | 1.42 | 168.85M |
| 2029E | 250.31M | 1.55 | 161.50M |
| 2030E | 259.47M | 1.69 | 153.36M |
| 2031E | 268.11M | 1.85 | 145.17M |
| 2032E | 276.42M | 2.02 | 137.11M |
| 2033E | 284.54M | 2.20 | 129.29M |
| 2034E | 292.03M | 2.40 | 121.56M |
| Terminal | 4.49B | 2.40 | 1.87B |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.